Targeting the cGAS–STING pathway has been considered a novel therapeutic strategy to improve clinical efficacy for cancer immunotherapy22, and several clinical trials utilizing STING agonists, such as 5,6-dimethylxanthenone-4-acetic acid, ADU-S100, and MK-1454, in solid tumors have been completed and/or ongoing23. This evidence concerns the gene CGAS and cancer.